[go: up one dir, main page]

MA53873A - Compositions et procédés pour le traitement de la presbytie - Google Patents

Compositions et procédés pour le traitement de la presbytie

Info

Publication number
MA53873A
MA53873A MA053873A MA53873A MA53873A MA 53873 A MA53873 A MA 53873A MA 053873 A MA053873 A MA 053873A MA 53873 A MA53873 A MA 53873A MA 53873 A MA53873 A MA 53873A
Authority
MA
Morocco
Prior art keywords
presbyopia
compositions
treatment
methods
Prior art date
Application number
MA053873A
Other languages
English (en)
Inventor
Gerald Horn
Original Assignee
Presbyopia Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Presbyopia Therapies Inc filed Critical Presbyopia Therapies Inc
Publication of MA53873A publication Critical patent/MA53873A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14Details; Accessories therefor
    • A61J1/1412Containers with closing means, e.g. caps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA053873A 2018-10-10 2019-10-08 Compositions et procédés pour le traitement de la presbytie MA53873A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862743720P 2018-10-10 2018-10-10

Publications (1)

Publication Number Publication Date
MA53873A true MA53873A (fr) 2022-01-19

Family

ID=70161531

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053873A MA53873A (fr) 2018-10-10 2019-10-08 Compositions et procédés pour le traitement de la presbytie

Country Status (12)

Country Link
US (1) US10836760B2 (fr)
EP (2) EP3863630A4 (fr)
JP (2) JP2022504746A (fr)
KR (1) KR20210076941A (fr)
CN (2) CN120899707A (fr)
AU (1) AU2019357979B2 (fr)
BR (1) BR112021006618B1 (fr)
CA (1) CA3114204A1 (fr)
MA (1) MA53873A (fr)
MX (2) MX2021004183A (fr)
SG (1) SG11202103033WA (fr)
WO (1) WO2020076769A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021006618B1 (pt) * 2018-10-10 2022-09-27 Presbyopia Therapies, Inc Composições e métodos para o tratamento da presbiopia
US20210251970A1 (en) 2018-10-10 2021-08-19 Presbyopia Therapies Inc Compositions and methods for storage stable ophthalmic drugs
WO2021222525A1 (fr) * 2020-04-30 2021-11-04 Eye Therapies, Llc Compositions de brimonidine et procédés d'utilisation
CN116847841A (zh) * 2020-10-13 2023-10-03 伦茨治疗股份有限公司 稳定眼科药物的组合物和储存方法
US20220347170A1 (en) * 2021-04-28 2022-11-03 Lenz Therapeutics, Inc. Method of Reducing Brow Ache
US12180206B2 (en) 2021-11-17 2024-12-31 Lenz Therapeutics Operations, Inc. Aceclidine derivatives, compositions thereof and methods of use thereof
CN116459251B (zh) * 2022-01-18 2024-12-13 苏州普乐康医药科技有限公司 一种含西维美林的眼用制剂及其制备方法和应用
TW202329958A (zh) * 2022-01-25 2023-08-01 張金明 西維美林水溶液組合物和使用方法
US20230310380A1 (en) * 2022-04-05 2023-10-05 Alan Neil Glazier Methods, devices, and systems for treating lens protein aggregation diseases
CN119700989A (zh) * 2023-09-28 2025-03-28 苏州普乐康医药科技有限公司 一种α-肾上腺素受体激动剂眼用组合物及其用途
US12414942B1 (en) 2024-03-15 2025-09-16 Lenz Therapeutics Operations, Inc. Compositions, methods, and systems for treating presbyopia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0632649B2 (ja) * 1986-02-20 1994-05-02 ロ−ト製薬株式会社 液状医薬品包装体
EP0648118A1 (fr) * 1992-07-02 1995-04-19 Telor Ophthalmic Pharmaceuticals, Inc. Procedes et produits permettant de traiter la presbytie
JP3849736B2 (ja) * 1998-04-13 2006-11-22 ライオン株式会社 易酸化物質又はこれを含む組成物の包装体及び易酸化物質の安定化方法
US6291466B1 (en) 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
US20090297566A1 (en) * 2004-12-27 2009-12-03 Brinkman Kyle R Oxygen-impervious packaging with optional oxygen scavenger, stabilized thyroid hormone compositions and methods for storing thyroid hormone pharmaceutical compositions
ES2329161T3 (es) 2006-12-18 2009-11-23 Jorge Luis Benozzi Composiciones oftalmicas de estimulantes parasimpaticos y antiinflamatorios para su uso en el tratamiento de la presbicia.
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
EP4272743A3 (fr) 2011-09-20 2024-07-10 Allergan, Inc. Compositions et procédés pour le traitement de la presbytie, de l'hypermétropie faible et de l'astigmatisme irrégulier
US9089562B2 (en) 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US20190038609A1 (en) * 2013-08-28 2019-02-07 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
US9320709B2 (en) * 2013-08-28 2016-04-26 Presbyopia Therapies Llc Storage stable compositions and methods for the treatment of refractive errors of the eye
US10307408B2 (en) * 2013-08-28 2019-06-04 Presbyopia Therapies, LLC Contact lens compositions and methods for the treatment of presbyopia
CA2987787C (fr) * 2015-06-18 2023-06-27 Presbyopia Therapies, LLC Compositions pour l'amelioration de la vision de loin et pour le traitement de l'ametropie de l'oeil
KR20180052130A (ko) * 2015-09-24 2018-05-17 앙코르 비전, 인코포레이티드 리포산 콜린 에스테르 조성물, 및 생체적합성 안과용 제형의 생성 방법
KR102487614B1 (ko) * 2015-10-06 2023-01-12 에이치엘비테라퓨틱스 주식회사 티모신 β4를 포함하는 안약의 제조방법
CA3017755A1 (fr) * 2016-03-17 2017-09-21 Presbyopia Therapies, LLC Compositions et methodes de traitement de la presbytie
BR112021006618B1 (pt) * 2018-10-10 2022-09-27 Presbyopia Therapies, Inc Composições e métodos para o tratamento da presbiopia

Also Published As

Publication number Publication date
MX2021004183A (es) 2021-10-26
CN113518620A (zh) 2021-10-19
JP2024156863A (ja) 2024-11-06
AU2019357979A1 (en) 2021-04-29
KR20210076941A (ko) 2021-06-24
WO2020076769A1 (fr) 2020-04-16
US20200115377A1 (en) 2020-04-16
EP4552651A3 (fr) 2025-07-16
JP2022504746A (ja) 2022-01-13
BR112021006618A2 (pt) 2021-07-06
MX2025001677A (es) 2025-03-07
BR112021006618B1 (pt) 2022-09-27
AU2019357979B2 (en) 2025-09-18
CN120899707A (zh) 2025-11-07
US10836760B2 (en) 2020-11-17
SG11202103033WA (en) 2021-04-29
EP3863630A1 (fr) 2021-08-18
EP3863630A4 (fr) 2022-06-29
EP4552651A2 (fr) 2025-05-14
CA3114204A1 (fr) 2020-04-16

Similar Documents

Publication Publication Date Title
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
EP3947715A4 (fr) Procédés et compositions pour le traitement du cancer
EP3555077A4 (fr) Compositions et procédés pour le traitement du cancer
EP3630072A4 (fr) Procédés et compositions pour le traitement d'une somnolence excessive
EP3612215A4 (fr) Compositions et procédés pour le traitement d'inflammation pulmonaire
EP3341391A4 (fr) Compositions et procédés pour le traitement de la douleur
EP3377516A4 (fr) Procédés et compositions pour le traitement du cancer
EP3908601A4 (fr) Procédés et compositions pour le traitement du cancer
EP3390642A4 (fr) Compositions et procédés pour le traitement de rétinite pigmentaire 18 et de rétinite pigmentaire 13
EP3801578A4 (fr) Méthodes et compositions pour le traitement de c. difficile
EP3448421A4 (fr) Procédés et compositions pour la prévention et le traitement d'adhérences chirurgicales
EP3405172A4 (fr) Procédés et compositions pour le traitement du vieillissement cutané
MA52961A (fr) Compositions et procédés pour la réduction ou le traitement d'une inflammation
EP3801478A4 (fr) Méthodes et compositions pour la prévention ou le traitement de la calciphylaxie
EP3429609A4 (fr) Compositions et procédés pour le traitement de déficits en collagène de type vii
MA55218A (fr) Eskétamine pour le traitement de la dépression
EP3331526A4 (fr) Enzymes de dégradation de la nicotine pour le traitement d'une dépendance à la nicotine et d'un empoisonnement à la nicotine
EP3688023A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3681498A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3638293A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3541379A4 (fr) Compositions pour le traitement de l'hypertension
MA55093A (fr) Méthodes et compositions pour le traitement du cancer
EP3365014A4 (fr) Méthodes et compositions pour le traitement de la mastocytose systémique
EP3368048A4 (fr) Méthodes et compositions pour le traitement de l'amyloïdose
MA52199A (fr) Compositions et procédés de traitement de la dystrophie maculaire